First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study

IF 40.1 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2026-10-01 DOI:10.1016/j.jhep.2026.10.002

Stephen L. Chan,Masatoshi Kudo,Bruno Sangro,Robin Kate Kelley,Jee Hyun Kim,Binh Pham,Jung Yong Hong,Dirk-Thomas Waldschmidt,Donatella Marino,René Gerolami,Adam M. Burgoyne,Gianluca Masi,Robert John Walsh,Jens U. Marquardt,Ugochinyere Emeribe,Kavitha Balaji,Peng Sun,Boris Baur,Lorenza Rimassa

引用次数: 0

查看原文本刊更多论文

一线durvalumab和tremelimumab治疗预后不良不可切除的肝细胞癌：IIIb期单臂SIERRA研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.